Wilmer Cutler Pickering Hale and Dorr advised Solid Biosciences Inc. on the deal. Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
Solid Biosciences’ $109 Million Private Placement
Arbor Biotechnologies’ Partnership with 4D Molecular Therapeutics
Wilmer Cutler Pickering Hale and Dorr represented Arbor Biotechnologies in the transaction. Arbor Biotechnologies announced a strategic partnership with 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT). As part of...
Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
Air Space Intelligence’s$34 Million Series B Financing Round
Wilmer Cutler Pickering Hale and Dorr represented Air Space Intelligence in the transaction. Air Space Intelligence (ASI) announced the completion of a $34 million Series B funding round....
Celldex Therapeutics’ $230.5 Million Common Stock Offering
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
Arvinas’ $350 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr advised Arvinas, Inc. on the transaction. Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas”) announced that it entered into a securities purchase agreement with a...
State Street Corporation’s $1.5 Billion Notes Offering
Wilmer Cutler Pickering Hale and Dorr represented State Street Corporation in the offering, and Cravath, Swaine & Moore represented the underwriters. State Street Corporation (NYSE: STT)...
Fnality’s £77.7 Million Series B Funding Round
Wilmer Cutler Pickering Hale and Dorr represented Depository Trust & Clearing Corporation in the transaction. Fnality announced it has secured £77.7M (approximately $97.39 million) in Series B...
WEX’s $250 Million Acquisition of Payzer
Wilmer Cutler Pickering Hale and Dorr is representing WEX in the transaction. WEX (NYSE: WEX) announced the signing of a definitive agreement to acquire Payzer. Pursuant to...
Aleph’s $11.5 Million Series A Financing Round
Wilmer Cutler Pickering Hale and Dorr is advising Aleph on the transaction. Aleph announced its Series A financing round as it emerged from stealth mode. The round was...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Hawkeye 360’s $10 Million Series D-1 Financing
Wilmer Cutler Pickering Hale and Dorr represented HawkEye 360, Inc. in the transaction. HawkEye 360, Inc. announced the subsequent closing of its Series D-1 Preferred Stock financing, which was...